In this context, the combination of estrogen therapy and GLP-1 receptor agonists represents perhaps the most metabolically direct version of the integrated approach this article has been building toward
Appetite suppression can lead to under-eating, which may reduce energy levels if protein and calories are too low
The conversation around GLP-1 medicines was no longer only about diabetes
These can include hormonal shifts, stomach troubles, and even changes in menstrual cycles
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, reveals that the medication suppresses signaling in the brains reward center thought to be involved in food noisebut only temporarily
This article explores the science behind L-cell activation and provides evidence-based strategies to optimize these remarkable cells through diet, lifestyle, and targeted nutrients